Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Axsome Therapeutics, Inc.    AXSM

AXSOME THERAPEUTICS, INC.

(AXSM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/19/2021 Date
80.44(c) 79.5(c) 79.89(c) 76.75(c) 76.96(c) Last
357 008 289 129 154 918 234 939 243 112 Volume
+3.21% -1.17% +0.49% -3.93% +0.27% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -99,9 M - -
Net cash position 2020 117 M - -
P/E ratio 2020 -28,8x
Yield 2020 -
Sales 2021 12,1 M - -
Net income 2021 -142 M - -
Net cash position 2021 124 M - -
P/E ratio 2021 -20,4x
Yield 2021 -
Capitalization 2 874 M 2 874 M -
EV / Sales 2020 -
EV / Sales 2021 227x
Nbr of Employees 53
Free-Float 79,0%
More Financials
Company
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for... 
More about the company
Notations Surperformance© of Axsome Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about AXSOME THERAPEUTICS, INC.
01/11AXSOME THERAPEUTICS : SMBC Nikko Initiates Axsome Therapeutics With Outperform R..
MT
01/08AXSOME THERAPEUTICS : Jefferies Starts Axsome Therapeutics at Buy With $129 Pric..
MT
01/04MYOVANT SCIENCES : Appoints David Marek to Lead Subsidiary
MT
2020AXSOME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
2020AXSOME THERAPEUTICS : Launches Phase 3 Trial of AXS-05 in Patients With Alzheime..
MT
2020AXSOME THERAPEUTICS : Reports Positive Results from Late-Stage Trial of Migraine..
MT
2020Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's D..
GL
2020Axsome Therapeutics Announces Positive Efficacy and Safety Results from the P..
GL
2020AXSOME THERAPEUTICS : Mizuho Starts Axsome Therapeutics at Buy With $120 Price T..
MT
2020Axsome Therapeutics Reports Positive Data From Trial of AXS-05 in Patients Wi..
MT
2020AXSOME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
2020Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS..
GL
2020Cantor Fitzgerald Adjusts Axsome Therapeutics' Price Target to $161 from $131..
MT
2020Axsome Therapeutics Delivers Positive Results From Phase 2 Trial of Anti-Depr..
MT
2020Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AX..
GL
More news
News in other languages on AXSOME THERAPEUTICS, INC.
2020AXSOME THERAPEUTICS, INC. : Veröffentlichung des Jahresergebnisses
2020AXSOME THERAPEUTICS, INC. : publication des résultats annuels
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2019AXSOME THERAPEUTICS INC : Veröffentlichung des Jahresergebnisses
2019AXSOME THERAPEUTICS INC : publication des résultats annuels
More news
Analyst Recommendations on AXSOME THERAPEUTICS, INC.
More recommendations
Chart AXSOME THERAPEUTICS, INC.
Duration : Period :
Axsome Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXSOME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 147,14 $
Last Close Price 76,96 $
Spread / Highest target 173%
Spread / Average Target 91,2%
Spread / Lowest Target -15,5%
EPS Revisions
Managers and Directors
NameTitle
Herriott Tabuteau Chairman, President & Chief Executive Officer
Mark L. Jacobson Chief Operating Officer & Secretary
Nick Pizzie Chief Financial Officer
Cedric O'Gorman Senior VP-Clinical Development & Medical Affairs
Roger A. Jeffs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AXSOME THERAPEUTICS, INC.-5.54%2 874
GILEAD SCIENCES, INC.15.12%84 074
VERTEX PHARMACEUTICALS-1.87%60 305
REGENERON PHARMACEUTICALS10.51%56 349
WUXI APPTEC CO., LTD.6.43%53 987
BEIGENE, LTD.38.04%32 523